吴柳盛,刘继先,乌 达.PD-1/PD-L1免疫抑制剂在非小细胞肺癌免疫治疗中的研究进展[J].肿瘤学杂志,2021,27(9):710-715. |
PD-1/PD-L1免疫抑制剂在非小细胞肺癌免疫治疗中的研究进展 |
Research Progress on Application of PD-1/PD-L1 Immune Checkpoint Blocker Tumor Immunotherapy to Inhibit Signaling Pathways in Non-small Cell Lung Cancer |
投稿时间:2020-10-28 |
DOI:10.11735/j.issn.1671-170X.2021.09.B003 |
|
|
中文关键词: PD-1/PD-L1 免疫检查点抑制剂 肿瘤免疫治疗 非小细胞肺癌 |
英文关键词:PD-1/PD-L1 immune checkpoint blockers tumor immunotherapy non-small cell lung cancer |
基金项目:广东省自然科学基金面上项目(2018A030313762);深圳市科技计划资助项目(JCYJ20180228162607111) |
|
摘要点击次数: 1038 |
全文下载次数: 279 |
中文摘要: |
摘 要:近年来免疫检查点领域研究进展迅速,众多新药相继出现,其中包括程序性细胞死亡蛋白1(programmed cell death protein 1,PD-1)单抗Pembrolizumab和Nivolumab,程序性细胞死亡蛋白配体1(programmed cell death protein ligand 1,PD-L1)单抗Atezolizumab。免疫检查点PD-1/PD-L1抑制剂给EGFR突变阳性非小细胞肺癌患者带来更多的生存获益,正逐渐改变国内外EGFR突变阳性晚期非小细胞肺癌的治疗模式。全文对PD-1/PD-L1为靶向的肿瘤免疫治疗在晚期EGFR突变阳性非小细胞肺癌患者治疗中的研究进展进行综述。 |
英文摘要: |
Abstract: In recent years, research in the field of immune checkpoints has progressed rapidly and many new drugs have emerged, including PD-1 monoclonal antibodies: Pembrolizumab and Nivolumab, PD-L1 monoclonal antibody Atezolizumab. Immune checkpoint PD-1/PD-L1 injection brings survival and remission time to chemotherapy time for EGFR mutation-positive non-small cell lung cancer patients, and it is gradually changing the EGFR mutation-positive advanced non-small cell lung cancer(NSCLC) treatment mode. Here is an overview of the progress in the treatment of non-small cell lung cancer using tumor immunotherapy implanted with the immune checkpoint PD-1/PD-L1 that inhibits the signaling pathway. |
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |